David G. Maloney

TL;DR: New approaches aimed at reducing the incidence of grade 2 to 4 acute GVHD might improve survival after allogeneic HCT after nonmyeloablative conditioning.

TL;DR: Patients with relapsed/refractory B-ALL enrolled in a phase 1/2 clinical trial evaluating lymphodepletion chemotherapy followed by CD19 CAR T-cell therapy who might benefit from consolidation strategies such as allogeneic HCT are studied.

TL;DR: Analysis of clinical and treatment characteristics, serum biomarkers, and CAR T-cell manufacturing and pharmacokinetic data showed that a lower pre-lymphodepletion serum lactate dehydrogenase (LDH) level and a favorable cytokine profile, defined as serum day 0 monocyte chemoattractant protein-1 (MCP-1) and peak interleukin-7 (IL-7) concentrations above the median, were associated with better PFS.

TL;DR: CD19 CAR-T cell immunotherapy with concurrent ibrutinib for R/R CLL were well tolerated, with low CRS severity, and led to high rates of MRD-negative response by IGH sequencing.

TL;DR: A nonmyeloablative conditioning regimen consisting of 2 Gy total body irradiation +/− fludarabine, 30 mg/m²/day x 3 days, to condition elderly or ill patients with hematological malignancies for allogeneic hematopoietic cell transplantation (HCT) and found there was a trend for a higher probability of achieving CR in pts with chronic GVHD.